Metabolic HealthMajor Obesity Trials May Miss the Full Burden of GLP-1 Nausea
Nausea is a common side effect of obesity medicines, but major trials may not capture its full impact on daily life. This narrative review examined how liraglutide, semaglutide, and tirzepatide trials measured nausea. Across the three trial programs, investigators recorded spontaneously reported symptoms using a standard safety reporting system rather than validated questionnaires designed specifically for nausea. Meanwhile, the trials used carefully developed tools to assess quality of life. The authors argue that this measurement imbalance may help explain why patients stop treatment more often in everyday practice than trial tolerability figures might suggest. However, the abstract does not establish that connection or quantify missed symptoms. Patients and clinicians should discuss how nausea affects eating and daily activities, not just whether it occurs. This summary is based on the abstract only.
